Tags

Type your tag names separated by a space and hit enter

Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances.

Abstract

Recent years have seen a dramatic increase in the number of clinical trials investigating the potential efficacy of medicinal cannabinoids for the symptomatic treatment of chronic pain and spasticity in multiple sclerosis (MS). A number of different cannabinoids have been used, including: delta9-tetrahydrocannabinol (THC) itself; the synthetic delta9-THC, dronabinol; a 1:1 ratio of delta9-THC:cannabidiol (Sativex); and the synthetic delta9-THC metabolites CT-3 and nabilone. Other Cannabis extracts have also been tested. While 2-3 years ago there was little consensus in the literature, now the majority of studies are beginning to suggest that cannabinoids are useful in the treatment of MS in at least a subset of individuals. Their adverse side-effect profile has generally been mild compared with other drugs used for pain and spasticity; nonetheless, there is still concern about potential long-term side effects, particularly psychiatric side effects and effects on fetal development.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    University of Otago, Department of Pharmacology & Toxicology, School of Medical Sciences, Dunedin, New Zealand. paul.smith@stonebow.otago.ac.nz

    Source

    Expert review of neurotherapeutics 7:9 2007 Sep pg 1157-63

    MeSH

    Cannabinoids
    Clinical Trials as Topic
    Humans
    Mental Disorders
    Multiple Sclerosis
    Pain
    Practice Patterns, Physicians'

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    17868014

    Citation

    Smith, Paul F.. "Symptomatic Treatment of Multiple Sclerosis Using Cannabinoids: Recent Advances." Expert Review of Neurotherapeutics, vol. 7, no. 9, 2007, pp. 1157-63.
    Smith PF. Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. Expert Rev Neurother. 2007;7(9):1157-63.
    Smith, P. F. (2007). Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. Expert Review of Neurotherapeutics, 7(9), pp. 1157-63.
    Smith PF. Symptomatic Treatment of Multiple Sclerosis Using Cannabinoids: Recent Advances. Expert Rev Neurother. 2007;7(9):1157-63. PubMed PMID: 17868014.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. A1 - Smith,Paul F, PY - 2007/9/18/pubmed PY - 2007/10/19/medline PY - 2007/9/18/entrez SP - 1157 EP - 63 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 7 IS - 9 N2 - Recent years have seen a dramatic increase in the number of clinical trials investigating the potential efficacy of medicinal cannabinoids for the symptomatic treatment of chronic pain and spasticity in multiple sclerosis (MS). A number of different cannabinoids have been used, including: delta9-tetrahydrocannabinol (THC) itself; the synthetic delta9-THC, dronabinol; a 1:1 ratio of delta9-THC:cannabidiol (Sativex); and the synthetic delta9-THC metabolites CT-3 and nabilone. Other Cannabis extracts have also been tested. While 2-3 years ago there was little consensus in the literature, now the majority of studies are beginning to suggest that cannabinoids are useful in the treatment of MS in at least a subset of individuals. Their adverse side-effect profile has generally been mild compared with other drugs used for pain and spasticity; nonetheless, there is still concern about potential long-term side effects, particularly psychiatric side effects and effects on fetal development. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/17868014/Symptomatic_treatment_of_multiple_sclerosis_using_cannabinoids:_recent_advances_ L2 - http://www.tandfonline.com/doi/full/10.1586/14737175.7.9.1157 DB - PRIME DP - Unbound Medicine ER -